Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2025 09:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
July 09, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 25, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 24, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 10, 2025 09:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
May 28, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
May 14, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
April 29, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented...
April 22, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
April 03, 2025 08:55 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Closes New Funding Round

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...